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ABSTRACT
Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli
(UPEC) are a serious problem worldwide, especially for females. Previous research in
our laboratory suggests that cranberry pectic oligosaccharides (cPOS) can reverse
dormant phenotypes in UPEC and therefore could prove useful in the prevention of
recurrent UTIs. This thesis focused on the purification and structure determination of
purified pectic oligosaccharides from cranberry hull extract. The research helped
established the structures of cPOS, provided high purity materials for biological testing,
and enabled further studies on the effect of different degrees of polymerization (DP) in
preventing dormant phenotypes in UPEC. More specifically, cPOS was determined to
be comprised of galacturonic acid residues by applying chemical derivatization methods.
Small quantities of terpene glycosides impurities in previously tested fractions were
removed successfully by implementing a trituration method. The bioassay results of
terpene glycosides-free cPOS confirmed the impurities were not responsible for the
bioactivity of cPOS. Finally, a semi-preparative HPLC method using HILIC
chromatography was established for the purification of cPOS components with variable
DPs. A preliminary structure-activity relationship based on the variation of cPOS DPs
is also described.
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CHAPTER 1

INTRODUCTION

Urinary tract infections (UTIs) are one of the most prevalent infectious diseases
worldwide, affecting people of all ages. It is estimated that 10.5 million UTI cases occur
1

annually in United states. Although most UTI patients only suffer from minimally
2

painful symptoms, the Centers for Disease Control and Prevention reports that UTIs are
responsible for 13,000 deaths annually. About 50% of women will experience a UTI at
3

some point in life, while 25% will experience a second, recurrent UTI within 6 months
after treatment of the initial UTI.

4

Uropathogenic Escherichia coli (UPEC) cause nearly 90% of all diagnosed UTIs.

5

UPEC forms biofilm-like intracellular bacterial communities (IBC) after invasion of
superficial facet cells in the bladder. This niche permits bacteria to reside and replicate
in intracellular environments that are predominantly protected from host innate
immunity and antibiotic treatments. UPEC can spread from IBCs to infect other urethral
epithelial cells. This process is proposed to allow UPEC to develop quiescent
intracellular reservoirs (QIRs) in the bladder tissue, resulting in bacteria reservoirs that
6

remain viable for months within the bladder tissue despite the absence of bacteria in the
urine. Multiple studies have used in vitro and in vivo models for UTIs to verify that
7,8

9

UPEC can invade bladder epithelial cells

10,11,12

and kidney epithelial cells.

13

Previous data supports that cranberry (Vaccinium macrocarpon) consumption may
hinder bacterial adherence to uroepithelial cells, potentially easing UTI related

1

symptoms.14 The cranberry plant is an evergreen shrub that was first cultivated in North
America. Cranberries are a major agricultural product in both the United States and
Canada.15 Additionally, there is positive clinical evidence that cranberry products can
be used prophylactically to reduce recurrent infections.16 Previous investigations of the
responsible cranberry constituents have mainly focused on proanthocyanidins,
particularly those with A-type linkages,17 and small organic acids.18 More recently,
researchers have focused on the potential involvement of cranberry complex
carbohydrates for beneficial effects against UPEC.

15,19

Our lab previously discovered

that cranberry xyloglucan can interfere with biofilm formation by UPEC.20 More
recently, we discovered that cranberry pectic oligosaccharides (cPOS) prevent
quiescence in the UPEC strain CFT073.21
In previous work,22 iridoid terpene glycosides were identified in fractions
containing cPOS following chromatographic separations. The removal of iridoids is
necessary to prove the activity of cPOS on UPEC in our biological assays. Our
separation approach leveraged the differential solubility of the iridoids and cPOS in
ethanol and water. HPLC and NMR spectroscopy were used to measure the residual
impurities in the cPOS fraction, and the iridoid-free cPOS was then tested in a persister
cell viability assay.
Previously, we used NMR spectroscopy to determine that the structure of cPOS is
comprised of repeating galacturonic acid units. However, the NMR approach was
insufficient

for

differentiating

between

galacturonic

and

glucuronic

acid

monosaccharide units. In this thesis, we pursued a chemical derivatization approach to
complement the previous NMR studies. Specifically, cPOS was hydrolyzed, modified

2

by a 1-phenyl-3-methyl-5-pyrazolone (PMP) reaction, and studied by HPLC in
comparison to the appropriate standards. These experiments confirmed that cPOS is
comprised of galacturonic acid monomers.
Additional studies in this thesis were aimed at optimizing the separation of
individual components of cPOS from a complex mixture. cPOS is a mixture of
oligosaccharides with varying degrees of polymerization (DP). The effect of DP on the
bioactivities of cPOS are currently unknown. The high polarity and water solubility of
cPOS makes separation of its individual components challenging. We developed an
HPLC method using HILIC chromatography to separate cPOS constituents of varying
DPs. These studies may ultimately help resolve structure–activity relationships (SAR)
related to cPOS degree of polymerization and reversal of UPEC quiescence.

3

CHAPTER 2

REVIEW OF LITERATURE

Oligosaccharides have been studied for their effects on various biological processes,
including inhibition of bacterial translation and interruption of cell wall biosynthesis.

23

In addition, oligosaccharides are critical mediators of cancer, cellular recognition and
microbial pathogenesis. Respectively, oligosaccharides may serve as potential
24

treatments for various diseases, ranging from bacterial infections to type II diabetes.

25

While oligosaccharide natural products possess a wide spectrum of potential biological
activities, they are relatively underrepresented in pharmacopeia. Generally, the
26

chemical investigation of oligosaccharides is difficult as compared to other classes of
molecules, such as linear peptides and oligonucleotides. The branched structures of
oligosaccharides impede amplification methods like polymerase chain reaction (PCR).
Therefore, procuring oligosaccharides by direct isolation from natural products is
preferred,

27,28

although this is complicated by their water-soluble nature. Sometimes, to

maximize the activity of oligosaccharides, modification such as esterification and
glycosylation would be performed. Also, these polar, functionalized oligosaccharides
29

can be present at negligible concentrations, and thus are more challenging to detect,
isolate and identify than other natural products.

26

One of the more well studied examples are human milk oligosaccharides (HMO).
These sialylated oligosaccharides and glycans were first discovered as a prebiotic
“bifidus factor”, which helps shape a healthy intestinal microbiota composition for
30

4

infants. HMO promote the proliferation of beneficial bacteria by serving as a metabolic
substrate. Sialylated human milk oligosaccharides enhance the newborn immature
31

immune system and are crucial for the proper development and well-being of the gut.

32

Like other dietary oligosaccharides, cranberry oligosaccharides have shown
various bioactivities, such as inhibition of bacterial adhesion, enhanced growth of
33

commensal bacteria, and reduced biofilm formation.
34

14,35

These soluble oligosaccharides

make up to higher than 20% w/w in many cranberry materials. However, the
15

contribution of oligosaccharides to the proposed health benefits of cranberry are largely
unresolved.
Since cranberry is well known for its contributions to urinary tract health,
understanding the potential contributions of each constituent may aid in optimizing
cranberry products. Oligosaccharides may play a role in UTI prevention since these may
be found in the urine. Coleman et al. demonstrated that an octasaccharide
arabinoxyloglucan, a water soluble type of hemicellulose oligosaccharide isolated from
cranberry, could be isolated from the urine of swine that were fed a cranberry product.

19

Moreover, this molecule demonstrated antiadhesion properties against bacteria. This
suggests that dietary oligosaccharides may be similarly excreted into human urine.
Pectic oligosaccharides (POS) are the hydrolysis products of pectin. Pectins are
high molecular weight (MW) structural polysaccharides found inside the lamella of
primary cell walls within almost all higher plant tissues. Pectin is a complex of acidic
37

polymers which is comprised of homogalacturonic and branched rhamnogalacturonic
regions. These pectins are broken down by natural enzymes during fruit ripening and
softening, resulting in lower molecular weight (MW) oligomers with different degrees

5

of polymerization (DP). Pectin is abundant in whole fresh cranberries, and with the
38

addition of heat and sugar during the juice making process, pectins can induce gel
formation in the juice. Therefore, commercial cranberry juice is treated with pectinase
39

macerations before filtering to increase juice yields. This suggests the inclusion of
40

significant pectic oligosaccharides in consumer cranberry products such as juice.
POS can be produced from agricultural byproducts, further enhancing the potential
for developing biomedicines and/or functional foods. For instance, the low-calorie and
odorless POS can be used in anti-obesity diets and the non-digestible property enables
41

POS to selectively affect bacteria flora in the colon. Notably, pectic oligosaccharides
42

also have immunomodulatory and anti-inflammatory

43,44

antioxidant activity

45

activity. POS possess

and are reported to provide potential protection against

cardiovascular diseases. Individual cPOS molecules from cranberry are generated from
46

cranberry pectin by various treatment methods, such as enzymatic, chemical and
47

physical

41

48

methods. Among them, enzymatic treatment for POS degradation is

considered as the most common due to the minimum chemical modifications as
compared to other pretreatment methods.

49

It has been reported that endo-

polygalacturonase can randomly cleave the glycosidic bond of the α-(1–4)polygalacturonan in pectin. Also, pectin methyl esterase and pectin acetyl esterase can
49

remove methyl esters and acetyl groups on galacturonic acid residues.

50

As mentioned previously, the pectinase enzyme mixtures are used to degrade cell
wall structures biochemically to increase juice production. Pectinase includes pectin
lyase and pectate lyase, both of which are able to cleave the smooth region of pectin, a
region of α-(1–4) linked D-galacturonic acid residues, and form α-(1–4)-D-GalpA

6

residues containing a 4,5-unsaturated galacturonic acid methyl ester at the non-reducing
end. De-esterified products treated with of Klerzyme 150 pectinase, a pectinase enzyme
51

mixture, resulted in unsaturated oligosaccharides after heat treatment. Interestingly, our
52

group previously isolated unsaturated methyl-esterified galacturonic acid from a
cranberry fraction that had been treated with same pectinase.

21

Further research is required to understand the possible roles and uses of cPOS in
UTI prevention. While cPOS has been shown to inhibit UPEC from residing in a
quiescent state, the impact of oligosaccharide degree of polymerization is unknown.
53

Furthermore, studies of cPOS on UPEC persister cells have been hindered by impurities
that remain following various chromatographic separations. Also, the monosaccharide
composition of cPOS has yet to be proven using chemical derivatization methods. The
research presented in this thesis helps overcome these current limitations in our
knowledge regarding the chemical nature of cPOS and its biological effects against
UPEC.

7

CHAPTER 3

METHODOLOGY
3.1 Equipment
1D and 2D NMR (HSQC) experiments were collected on an Agilent NMR 500
MHz spectrometer (Varian VNMRS 500MHz, Agilent Technologies) in D2O (99.99%,
Sigma-Aldrich) at 25 °C. LC/MS analysis was performed on a Shimadzu Prominence
UFLC system coupled to an AB Sciex QTRAP 4500 mass spectrometer with
electrospray ionization source in the negative ion mode. Flash chromatography used a
Combiflash Rf200 equipped with a 100 g C18 RediSepRf High Performance Gold
column (Teledyne ISCO). Semi-preparative HPLC experiments were performed on a
Shimadzu Prominence i-series HPLC, using TSKgel Amide-80, 7.8 mm I.D x 30 cm,
10 µm column. Analytical HPLC experiments were also performed on the Shimadzu
Prominence i-series HPLC using a 4.6 × 250 mm, 5 µm TSKgel Amide-80 HR HILIC
column. Centrifugation was conducted with an Eppendorf 5804 centrifuge. All solvents
used were HPLC grade and purchased from Sigma-Aldrich Chemical Co. (St. Louis,
MO, USA).

3.2 Fractionation of cranberry (V. macrocarpon) materials
A pectinase (Klerzyme 150, DSM Food Specialties, IN) degraded cranberry hull
extract (1.0 g) was dissolved in 20 mL distilled water and fractionated by reversed phase
flash

chromatography.

After

purging

and pre-conditioning

a

Combi-Flash

chromatography instrument, a C18 column (100 g C18 RediSepRf High Performance

8

Gold) was loaded with the cranberry hull extract sample and sequentially eluted with
500 mL of distilled H2O (Fraction Cranf1W, 752 mg, 37.6%), 500 mL of 15%
methanol/water (Fraction Cranf1b, 480 mg, 24.0%), and finally 500 mL of MeOH
(Fraction Cranf1M, 564 mg, 28.2%) at 35 mL/min. The three fractions were
concentrated by rotary evaporation and lyophilization and stored at -20 °C.

3.3 Trituration of active fractions
Trituration of fraction Cranf1b to remove iridoid terpenes was accomplished by
sonicating 200 mg Cranf1b in 30 mL 95% ethanol/water and then centrifuging the solids
at 17,000 x g for 8 min. The collected solids were then dissolved in deionized (DI) H2O
and lyophilized. The trituration step was repeated twice prior to further separation by
PGC chromatography to provide sample cPOS-t (91.7%, w/w dry). 1H NMR data and
analytical HPLC analysis of the resulting products were assessed to determine the
iridoid terpenes were successfully removed by trituration. HPLC was accomplished on
a Prominence i-series system (Shimadzu) using a TSKgel Amide-80 HR HILIC column
(4.6 × 250 mm, 5 µm, TOSOH Bioscience, Tokyo, Japan) with a 1.0 mL/min flow rate
and 35 °C while monitoring at UV 235 nm (20 µL injections of a 10 mg/mL sample).
The column was first eluted with 80% ACN/water (+0.1% formic acid) for 2 min,
followed by a linear gradient to 40% ACN/water (+0.1% formic acid) for 20 min and
then held for 5 min.

3.4 cPOS separation by chromatography on porous graphitized carbon

9

Cranf1b was further fractionated using porous graphitized carbon (PGC)
chromatography (1 g cartridges, ThermoFisher Scientific). The PGC cartridge was first
eluted with 50% ACN/water for cleaning and then equilibrated with distilled water for
conditioning. A total of 40 mg of Cranf1b was dissolved in 2 mL distilled water, loaded
onto the PGC cartridge, and eluted sequentially with 18 mL H2O, 12 mL 10%
ACN/water (+0.1% TFA), and 18 mL 30% ACN/water (+0.1% TFA). All fractions were
lyophilized and stored at -20 °C.

3.5 Structure determination of cPOS
All the individually collected fractions from step 3.3 were analyzed by LC/MS and
1D and 2D NMR spectroscopy for structure determination. The LC/MS analyses were
performed on an Amide-80 column using the HPLC conditions described above.
LC/MS were operated in negative ion mode and while scanning in a range from m/z 200
to m/z 2000. For NMR analysis, samples were deuterium exchanged twice by dissolving
in D2O (99.99%, Sigma-Aldrich) and shaking for 5 min. 1H and HSQC NMR
experiments were conducted on a 500 MHz NMR spectrometer at 25 °C, with
compounds dissolved at 10 mg/mL. 1H NMR spectra were acquired with 16 scans.
HSQC spectra were obtained with 4 scans per increment and 128 t1 increments.

3.6 Determination of monosaccharides composition by PMP-derivatization
The composition of the poly-galacturonic acid backbone of cPOS was determined
by acid hydrolysis of cPOS followed by derivatization with 1-phenyl-3-methyl-5pyrazolone (PMP). The strategy followed a previously published protocol as

10

follows.54,55 10 mg cPOS was hydrolyzed in 1 mL of 2 M TFA at 90 °C for 5 h. After
cooling to room temperature, the reaction mixture was centrifuged at 3000 rpm for 5 min.
The supernatant was evaporated in vacuo to remove residual TFA. The hydrolysate
mixture was dissolved in 1 mL distilled water and treated with 30 µL NaOH (0.3 M) and
20 µL PMP solution (0.5 M in methanol) for derivatization. The mixture was incubated
at 70 °C for 60 min, cooled to room temperature and neutralized with 30 µL of HCl
(0.3 M). The mixture was then extracted with 1 mL chloroform. The aqueous layer was
filtered by passing through a 0.45 µm syringe filter. Glucuronic acid (2.0 mM),
galacturonic acid (2.0 mM) and a distilled water blank were subjected to the identical
reaction conditions. HPLC analyses of PMP-labeled samples were conducted on a
Prominence i-series system (Shimadzu) using a BAKERBOND C18 column
(4.6 mm × 250 mm, 5 𝜇m, J.T. Baker Inc., Phillipsburg, NJ, USA). The injection volume
was 20 µL with a flow rate of 1.0 mL/min at 35 °C. Mobile phase A was 10%
ACN/water with 0.045% KH2PO4–0.05% triethylamine buffer (pH 7.5) and mobile
phase B was 100% ACN. The column was eluted with 6% B for 4 min, a gradient of 6–
12% B for 1 min and then 12% B for 20 min. The UV detection wavelength was 254 nm.

3.7 Purification of oligosaccharides with various degrees of polymerization
Oligosaccharides with different DPs in 10% PGC fraction were sequentially
purified by HPLC using a TOSOH Tskgel Amide-80 HR column (7.8 mm I.D x 30 cm,
10 µm) (TOSOH Bioscience) with a 1.6 mL/min flow rate and 35 °C while monitoring
at UV 235 nm (100 µL injections of a 20 mg/mL sample). The column was initially
eluted with 80% ACN/water (+0.1% formic acid) for 2 min, followed by a linear

11

gradient to 40% ACN/water (+0.1% formic acid) for 20 min and then held for 5 min.
Fractions corresponding to cPOS with different DPs were collected based on UV
absorbances and/or retention time and concentrated by lyophilization.

3.8 Persister cell viability assay and quiescence lawn assay
The persister cell viability assay was performed following a previously published
protocol.6 Briefly, E. coli strain CFT073 was streaked from cryo-stocks onto LB agar
plates and incubated overnight at 37 °C. A loopful of cells from the plate were added to
10 mL 0.4% glucose M9 minimal media in a 125 mL culture flask and incubated
overnight at 37 °C and 200 rpm. Cultures were diluted in fresh 0.2% glucose M9
minimal media to an optical density (OD600) of 0.1 (~108 CFU/mL) and grown in the
presence of ampicillin sodium (0.1 mg/mL) to generate persister cell fractions. The
cultures were incubated shaking (200 rpm) at 37 °C and viable counts were measured
at 0 h, 4 h, and 24 h by plating on LB media. Test cultures were treated with cPOS
fractions at 1-2 mg/mL. Control experiments included cultures without antibiotic (cPOS
only) and cultures without antibiotic or cPOS.
The quiescence lawn assay also followed a published protocol.6 Briefly, overnight
cultures of CFT073 were prepared in 0.4% glucose M9 minimal media as described
above for the persister cell viability assay. Bacteria from this culture were diluted to a
final concentration of 105 CFU in 4 mL of liquid overlay media (0.2% glucose M9
minimal media with 0.9% noble agar at 45 °C). Each 4 mL overlay inoculum was poured
over a prewarmed (37 °C) 0.2% glucose M9 minimal media agar plate immediately after
inoculation. These plates were allowed to solidify at room temperature with lids slightly

12

ajar. Test solutions were added to the overlay media and allowed to dry before
incubating the plate upside down at 37 °C for 24 h or 48 h. No growth of E. coli in the
overlay is considered to be quiescent if it is able to be reversed with the positive control
(3 co-spots of 5 µL of each tyrosine, lysine, and methionine, each at 0.1 mg/mL in H2O).

13

CHAPTER 4

RESULTS
4.1 Separation of iridoid terpene glycosides from cPOS
In previous work, three iridoid terpene glucosides (Figure 1) were identified as 6,7dihydromonotropein (a), monotropein (b) and deacetylasperulsidic acid (c) in fractions
containing cPOS following chromatographic separations. Iridoids were separated and
analyzed by ESI-TOF-MS in the negative ion mode (Figure 2). The major peak showed
two ions in negative mode at m/z 391.1204 and 389.1050, suggesting two co-eluted
molecules which were subsequently further separated by C18 column chromatography
as a and b, respectively. The second peak showed one negative ion at m/z 389.1050 (c).
Although these iridoid glucosides were minor impurities and inactive in the in vitro
quiescence inhibition assay (data not shown), the removal of iridoids was necessary to
prove the activity of cPOS on UPEC in our persister cell assay.
The separation approach described here was based on the differential solubility of
the iridoids and cPOS in ethanol and water. We found that these impurities could be
removed from the cPOS fraction by exploiting their differential solubility in ethanol.
Cranf1b was triturated with 95% aqueous ethanol prior to PGC separation, producing a
cPOS fraction devoid of iridoid glycosides (cPOS-t, 91.7%, w/w dry) as determined by
HPLC analysis (Figure 3) and 1H NMR analysis (Figure 4). 10 mg/mL solutions of
cPOS fraction and iridoid-deficient cPOS fraction (cPOS-t) were analyzed by HILIC
HPLC using UV-monitoring (235 nm). Figure 2 shows a comparison of pre- and posttriturated samples and demonstrates the successful removal of iridoid glucosides.

14

Moreover, the absence of typical 1H NMR signals corresponding to the double bonds
on the cyclopentanopyran scaffold of iridoid glucosides in cPOS-t further supports the
successful removal or iridoid terpenes from cPOS by the trituration method (Figure 4).
HSQC NMR analysis of the cPOS-t cranberry fraction revealed proton and carbon
resonances with chemical shifts characteristic for poly-uronic acids. Additional
structural features included a methoxy group at δH 3.70/ δC 52.8 and a vinylic methine
at δH 6.00/ δC 111.8 (Figure 5). UV absorption maxima at 235 nm was consistent with
the presence of an α, β-unsaturated carboxylic acid.
The cPOS-t fraction was tested in a persister cell viability assay and found to
maintain activity similar to cPOS (Figure 6,7). Treatment of E. coli CFT073 with both
cPOS and ampicillin resulted in >1000-fold fewer persister cells versus treatment with
ampicillin alone.20 A similar reduction of persister cells was obtained when conducting
the assay with cPOS-t (Figure 6). The viable cell counts in the E. coli CFT073 cultures
decreased slightly during the first 4 h of incubation in both the presence and absence of
ampicillin. By 24 h, E. coli CFT073 had grown to just over 109 CFU/mL in the absence
of ampicillin. In contrast, the presence of ampicillin reduced the viable counts an
additional ~1000-fold over the next 20 h, to about 106 CFU/mL. As shown by the results
in Figure 5, in the presence of 1 mg/mL cPOS and absence of ampicillin, E. coli CFT073
viable counts increased rapidly, reaching stationary phase within 4 h. Importantly, in
the presence of both the cPOS and ampicillin, E. coli CFT073 viable counts decreased
rapidly within 4 h, and reached a level of about 3 × 102 CFU/mL after 24 h.

15
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Figure 1. Structures of iridoid glucosides: 6,7-dihydromonotropein (a), and
deacetylasperulsidic acid (b) and monotropein (c).

Figure 2. LC-MS analysis in the negative ion mode of iridoid glucosides showing
extracted ions of m/z 391 and m/z 389.
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Figure 3. HILIC HPLC chromatogram of cPOS (Top) and cPOS-t (Bottom) at 235 nm.
6,7-dihydromonotropein (a), deacetylasperulsidic acid (b) and monotropein (c). Only
trace amount of iridoid glucosides remained in cPOS-t. Adapted from Sun et al.21
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Figure 4. 1H NMR spectrum (D2O, 500 MHz) of standards (purified 4-mer pectic
oligosaccharide and iridoids), and cPOS-t (triturated 10% PGC). The 1H NMR analysis
indicated the triturated 10% PGC was similar to 4-mer pectic oligosaccharide and
signals corresponding to the iridoids were absent.
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Figure 5. HSQC spectrum of cPOS-t (D2O, 500 MHz). The 1H and HSQC NMR spectra
of the active cranberry fraction revealed proton and carbon resonances with chemical
shifts characteristic for poly-uronic acids.

Figure 6. Persister cell viability treating with cPOS-t (CFT073+ampicillin+ cPOS-t) is
significantly different at 4 h (**- P ≤ 0.01) and 24 h (**-P ≤ 0.01), in comparison to
CFT073+ampicillin. CFT073 cell viability with (CFT073+cPOS-t) or without cPOS-t
treatment (CFT073) were evaluated as controls. cPOS-t: 2 mg/mL; ampicillin: 0.1
mg/mL. Adapted from Sun et al.21
19

Figure 7. Persister cell viability treating with cPOS (CFT073+ampicillin+ cPOS) is
significantly different at 4 h (**- P ≤ 0.01) and 24 h (***-P ≤ 0.01), in comparison to
CFT073+ampicillin. CFT073 cell viability with (CFT073+cPOS) or without cPOS
treatment (CFT073) were evaluated as controls. cPOS: 2 mg/mL; ampicillin: 0.1
mg/mL. Adapted from Sun et al.21

4.2 Verification of the cPOS monosaccharide composition by chemical
derivatization
Previously, our lab used NMR spectroscopy to determine the structure of cPOS is
comprised of repeating galacturonic acid units.22 However, the NMR approach is
limited in its ability to differentiate between galacturonic and glucuronic acid
monosaccharide units, since the two anomeric proton peaks generally used to
differentiate between different monosaccharide residues are very similar in the case of
these two sugars. Therefore, a chemical derivatization approach was applied to
complement the previous NMR studies. Specifically, cPOS was hydrolyzed, modified
by a 1-phenyl-3-methyl-5-pyrazolone (PMP) reaction, and analyzed by reversed-phase
HPLC with UV detection in comparison to the appropriate standards. By comparing
20

HPLC traces, the monosaccharide composition of cPOS was determined to be
comprised of galacturonic acid units. Figures 8B and 8C show the retention times for
PMP reaction products with glucuronic acid and galacturonic acid, respectively.
Comparison of retention time between cPOS hydrolyzed products (Figure 8D, tR= 6.0
min) and standard derivatives (PMP, tR = 3.3 min; glucuronic acid, tR = 4.6 min;
galacturonic acid, tR = 6.0 min) confirms that the cranberry POS oligosaccharides were
comprised of galacturonic acid units.
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Figure 8. Uronic acid identification of cPOS. cPOS, glucuronic acid and galacturonic
acid were derivitized with PMP and analyzed by HPLC as described in the Methods.
The stacked chromatograms show the results for reactions conducted with PMP without
an added carbohydrate (A); Glucuronic acid (B); Galacturonic acid (C); and cPOS
hydrolysate (D). The peak with a retention time at 6.0 min in D indicates that cPOS is
comprised of galacturonic acid. Adapted from Sun et al.21
4.3 Purification of cPOS for determining the effect of DP on UPEC phenotypes
With the active cPOS monosaccharide composition verified, we next sought to
enable structure-activity relationships (SAR) of cPOS components with respect to the
observed reversal of CFT073 quiescence. It is well recognized that DP is one of the
crucial factors with regard to the bioactivities of oligosaccharides.15,27 To assess the
effect of cPOS DP on reversal of CFT073 quiescence, a separation method was
developed for isolation of cPOS components with different DPs. Good separation was
ultimately achieved using hydrophilic interaction chromatography (HILIC) with
hydrophilic (amide) stationary phases and reversed-phase type eluents. In a HILIC
system, the surface forms a water-rich layer on the polar stationary phase, leaving a
water-deficient mobile phase, forming a liquid/liquid extraction system. The analytes
interact between these two layers. Compounds with higher polarity will elute later since
they have higher interaction with the stationary aqueous layer. As for oligosaccharides,
the oligomers with higher DPs have relatively higher polarity, which elute later while
oligomers with lower DPs elute earlier.
Taking previous analytical HILIC HPLC separation results into consideration,56 a
similar separation method with slight modifications was used to isolate cPOS. A solvent
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system comprised of acetonitrile and water with 0.1% TFA was the best mobile phase
for cPOS separation. The presence of TFA in eluting solvents increased the acidity
which resulted in a better separation for acidic compounds. In our case, since the
molecules of interest consisted of galacturonic acid oligomers, ensuring the molecules
were fully protonated was expected to give better separation, as well as increase the
consistency of each separation batch (Figure 9). A 1.5 mL/min flowrate with a semipreparative HILIC column provided chromatographic separation similar to using the
analytical column at 1.0 mL/min (Figure 9).

Figure 9. Analytical HILIC HPLC chromatography of cPOS by using TOSOH Tskgel
Amide-80 HR column (7.8 mm I.D x 30 cm, 10 µm), 1.0 mL/min.

The collection of cPOS components from the semipreparative separation was based
on the chromatographic peaks. Considering the non-polar impurities observed
previously, fractions were collected starting from fraction 1 (tR= 15 min) to fraction 10
(tR= 27 min) for bioassay analysis (Figure 10). All the combined eluents prior to 14.7
min were combined as fraction 0. By injecting 40 mg of cPOS-t, a total of 11 fractions
were obtained with sufficient material for testing in the quiescence bioassay.
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Figure 10. Preparative HILIC HPLC chromatography of cPOS by using TOSOH
Tskgel Amide-80 HR column (7.8 mm I.D x 30 cm, 10 µm), 1.5mL/min. For each 40
mg of cPOS-t, the certain amount of fractions 0−10 were obtained (fraction 0: 4.7 mg,
fraction 1: 1.4 mg, fraction 2: 1.6 mg, fraction 3: 1.0 mg, fraction 4: 1.6 mg, fraction 5:
1.7 mg, fraction 6: 2.9 mg, fraction 7: 1.9 mg, fraction 8: 3.0 mg, fraction 9: 3.5 mg and
fraction 10: 3.8 mg).
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Figure 11. 1H NMR spectrum (D2O, 300 MHz) of 11 fractions separated by preparative
HILIC HPLC.
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The semipreparative HILIC HPLC not only gave a good separation of impurities
and cPOS, but also separation of cPOS with different DPs. As shown in Figure 10, the
analysis of 1H NMR spectra of all 11 fractions indicated that fractions 0−2 were
impurities with only trace amounts of oligosaccharides while fractions 3−10 showed
resonances consistent with cPOS. This includes the typical proton signals of a vinylic
methine around δH 6.10 and methoxy group around δH 3.70. The successful separation
method using HILIC HPLC set the stage for preliminary structure–activity relationship
(SAR) analysis. According to the activity result (Figure 12), the activity variation of
each fraction suggested that the DPs of cPOS plays a role in reversing UPEC quiescence.
Only fraction 4 showed activity (5 µL spot; 10 mg/mL) while no obvious positive effects
of other obtained fractions were observed, indicating that only cPOS with a specific and
relatively low DP might be responsible for the observed activity. Further
characterization of the active fraction and comparison to the inactive ones will provide
further clues for the structural requirements for biological activity in this assay.
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Figure 12. CFT073 quiescence assay using glucose-free M9 plates. A colony of
actively growing CFT073 toothpicked into the agar plate as positive control; Sample
A: cPOS-t, (10 mg/mL); Sample B: Cranf1b, (10 mg/mL); Fractions 1 to 10 were
obtained from HPLC separation of cPOS-t, (10 mg/mL).
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CHAPTER 5

CONCLUSION

Polysaccharides exhibit a variety of biological functions and characterizing their
monosaccharide composition is a critical first step to understanding their structure and
function. Previously, our lab used 1H and HSQC NMR spectroscopy to deduce the
structure of cPOS, revealing chemical shifts for the active cranberry fraction consistent
with polyuronic acids. In this study, chemical derivatization was used to confirm that
cPOS is comprised of galacturonic acid residues. The smooth region of pectin is called
galacturonans which are linear chains of α-(1–4)-linked D-galacturonic acid. Hence,
cPOS is hypothesized to be the hydrolysis product of pectin.
Acid hydrolysis of cPOS followed by PMP derivatization required optimization.
Temperature and pH value are two crucial parameters for both the hydrolysis and
derivatization reactions. Galacturonic acid oligosaccharides are relatively more stable
than other saccharides.50 However, higher reaction temperatures will lead to degradation
of oligosaccharides. We used a moderate temperature (90 ℃ versus 120 ℃) and longer
reaction time (5 hours compare to 2 hours)57 to successfully hydrolyze our product.
During the derivatization step, carbanions are required to form a Schiff base and
subsequent reactions to generate derivatives, which means the reaction should be
conducted under basic conditions. Since uronic acids are more acidic than other sugars
due to their carboxylic acid, the addition of NaOH was necessary to adjust the pH and
facilitate the reaction.
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Three minor impurities, all iridoid glucosides, were previously identified by our
lab in the active 10% cPOS fraction obtained using porous graphitized carbon
chromatography. Specifically, these were identified as 6,7-dihydromonotropein,
deacetylasperulsidic acid and monotropein and found to be inactive in the quiescence
assay. Previous studies have shown that the iridoid glucosides monotropein and 6,7dihydromonotropein also lack antiadhesive effects against Escherichia coli.58,59 We
sought to remove these impurities to provide a more highly purified cranberry pectic
oligosaccharide sample for biological study. Based on the differential solubility in
ethanol of iridoid glucosides and cPOS, iterative trituration with 95% aqueous ethanol
proved successful for removing the iridoid impurities before PGC fractionation. HPLC
and 1H NMR analyses verified the removal of iridoid glucosides, and the persister cell
bioassay again confirmed that these were not responsible for the bioactivity of cPOS.
Degree of polymerization is another crucial factor to be determined when
characterizing the activity of cPOS against UPEC. Due to the limitation of column size,
our group previously only separated small quantities and determined the structures of
two pectic oligosaccharides, namely uG3m2 and UG4m3.21 In this thesis work, a semipreparative HPLC method using HILIC chromatography was developed for the
purification of cPOS components with variable DPs. 1H NMR results further confirmed
that cPOS with variable DPs could be separated from the complex mixture of
oligosaccharides. This method will be useful for future efforts to further investigate the
biological properties of cPOS oligosaccharides.
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APPENDIX
Anti-inflammatory effects of cPOS
1. Introduction
Cranberry is the fruit of the evergreen shrub Vaccinium macrocarpon and has been
extensively studied for benefits to human health, including urinary tract health15 and
anti-inflammation effects.60,61 Inflammation is an important process for protecting
against infections and healing wounds. However, inflammation is also implicated in
numerous chronic diseases, including cancer.62 Dietary sources of anti-inflammatory
compounds could therefore provide beneficial health outcomes. In previous
investigations of the anti-inflammatory properties of cranberry constituents,
investigators

have

focused

on

proanthocyanidins,

63

especially

A-type

proanthocyanidins, neglecting the potential contributions of cranberry oligosaccharide
64

constituents.
Yet, polysaccharides from botanical sources have previously shown various effects
on inflammation pathways. Some polysaccharides have been shown to increase the
expression of cytokines and chemokines, including tumor necrosis factor (TNF-α),
Interleukin-1β (IL-1β)65 and IL-6.66 On the contrary, some citrus pectins can exert antiinflammatory action. Also, bupleurum polysaccharides were found to up-regulate
phagocytic activities and inhibit secretion of inflammation related cytokines. This
67

68

multi-function can be referred as biological response modifiers (BRMs). Previously, our
lab found xyloglucan and pectic oligosaccharides in cranberry extract subfraction
Cranf1b. Xyloglucan, a hemicellulose, has been reported to attenuate inflammation
22

69
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and activate macrophages. However, how the effect of xyloglucans and pectic
65

oligosaccharides on the secretion of cytokines is unknown.
In this study, we tested the effects of cranberry extracts enriched in
oligosaccharides for modulation of the pro-inflammatory cytokines TNF-α, IL-1β, and
IL-6. An attempt to identify the active components was pursued using bioactivity guided
isolation.

2. Anti-inflammatory evaluation of oligosaccharide-rich cranberry extracts by
measuring TNF-α and IL-1β secretion by THP-1 cells
To evaluate the anti-inflammatory properties of cranberry extract, a model was
applied initially to examine effects against TNF-α and IL-1β. THP-1 cells were seeded
at a density of 5*104 cells per well in 48 well plate. PMA (25 ng/ml) was added to induce
differentiation for 48 hours. Next, the PMA was removed and cells were incubated with
PMA free medium for another 24 hours. LPS was added for 4 hours, then samples were
added and incubated for another 1 hour. Nigericin was then added for another 1 hour.
The supernatant was collected and IL-1β and TNF-α were measured by ELISA.
Nigericin is an inducer for inflammasome activation and boosts IL-1β secretion.
Inflammasome activation needs two inducers: LPS and nigericin. MCC is a positive
control small molecule that specifically inhibits inflammasome activation. Fraction
Cranf1b its PGC subfractions (Scheme 1) were tested and showed positive results for
the anti-inflammatory activity by IL-1β and TNF-α assays (Figure 13).
LPS stimulated the release of TNF-α (114.87 ± 5.98 pg/mL) and IL-1β (303.30 ±
40.38 pg/mL) whereas the blank control did not produce significant levels (12.53 ± 0.98
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pg/mL and 135.37 ± 26.39pg/mL, respectively). LPS and nigericin treatment also
resulted in elevated TNF-α (53.59 ± 9.68 pg/mL) and IL-1β (583.35 ± 72.52 pg/mL)
concentrations. Fraction S2 (70% water/30% ACN portion) at a concentration of 0.01
µg/mL was the most effective at reducing the secretion of TNF-α by 67% (37.97 ± 3.92
pg/mL), while none of the samples demonstrated a reduction in IL-1β secretion.

Scheme 1. Sample preparation for TNF-α and IL-1β assay. Sample preparation method
was detailed in Sections 3.2 and Section 3.4 of this thesis. Fraction S1: Cranf1b portion
and fraction S2: 70% water/30% ACN portion, highlighted in red, were determined to
be positive in TNF-α and IL-1β assay.
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Figure 13. Results of IL-1β and TNF-α assay for fractions obtained from sample
preparation of cranberry juice extract powder. Fraction S1: Cranf1b portion; fraction S2:
70% water/30% ACN portion; fraction S3: 90% water/10% ACN portion; fraction S4:
100% water portion. Data shown as mean ± SE.

3. Anti-inflammatory evaluation of cranberry extracts for modulating TNF-α and
IL-6 secretion
The previous experiments suggested that fraction S2 showed the most promise for
impacting pro-inflammatory cytokine production. This fraction had been generated
using porous graphitized carbon chromatography PGC 30% ACN fraction (Scheme 2).
To further separate this active fraction, an HPLC method was devised to for the
separation of oligosaccharides. The conditions were as follows: UV detector was set at
254 nm (Figure 14, pink trace), flow rate 1.5 mL/min. The TSKgel Amide-80 column
(10 µm, 7.8 mm I.D x 30 cm) was initially eluted with 60% ACN/water (+0.1% formic
acid) for 2 min, followed by a linear gradient to 40% ACN/water (+0.1% formic acid)
for 28 min and then held for 5 min.
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Similar to the previously described method, the anti-inflammation effects of HPLC
separation fractions from active fraction (70% water/30% ACN portion) was tested
using assays that measure IL-6 and TNF-α. THP-1 cells were seeded into 48 well plates
at a density of 50,000 cells/well in medium with PMA (25 nM) for 48 hours. Following
this period, cells were visually checked for adherence and proper morphology before
exchanging differentiation medium to serum free medium for 24 hours prior to sample
treatment. Test samples were weighed and dissolved in FBS free medium before being
diluted in cell culture medium at concentrations of 100 and 10 µg/mL. CE at these
concentrations were added to each respective set of wells for 1 hour before being
exposed to LPS at 1 µg/mL for 24 hours. Following LPS exposure, medium was
collected, centrifuged and assayed for IL-6 and TNF-α using respective ELISA kits.
LPS was able to stimulate the release of TNF-α (289.56 ± 25.97 pg/mL) and IL-6
(753.32 ± 12.33 pg/mL) into culture media whereas the blank control did not produce
significant levels (30.51 ± 2.16 pg/mL and 278.51 ± 36.42 pg/mL respectively). Fraction
S4 (first subfraction obtained from 70% water/30% ACN portion) at a concentration of
100 µg/mL was the most effective at reducing the secretion of TNF-α by 94% (17.13 ±
3.88 pg/mL) and at 100 µg/mL, IL-6 secretion was significantly attenuated by
approximately 73% (206.19 ± 7.44 pg/mL).
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Scheme 2. Further separation of active fraction (70% water/30% ACN portion). All
subfractions were tested for TNF-α and IL-6 assay. The active subfraction (S4) was
highlighted in red.

Figure 14. HPLC separation of the active S3 fraction (70% water/30% ACN portion).
A total of four subfractions (S4−S7) were obtained by HPLC separation. Fractions were
collected based on retention time (fraction S4: 2.0 min−7.0 min; fraction S5: 7.0
min−12.0 min; fraction S6: 12.0 min−17.0 min; fraction S7: 17.0 min−22.0 min).
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Figure 15. Results of IL-6 and TNF-α assays for fractions obtained from sample
preparation of cranberry juice extract powder. Fraction S1: Cranf1b portion; fraction S2:
Cranf1M; fraction S3: 70%water/30% ACN portion; S4−S7: four subfractions obtained
from HPLC separation of S3; S8: iridoid-rich fraction. Data shown as mean ± SE.

4. Anti-inflammatory evaluation of subfractions of cranberry extract in THP-1
monocytes
To further evaluate the anti-inflammatory properties of Cranberry Extract, LPS
sensitive, phorbol 12-myristate 13-acetate (PMA) differentiated THP-1 monocytes were
used. THP-1 monocytes were differentiated to macrophages according to previously
described methodologies.70 In brief, THP-1 cells were seeded into 24 well plates at a
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density of approximately 200,000 cells/mL and allowed to incubate for at least 24 hours
prior to PMA exposure. PMA was then added directly to each well at final concentration
of 25 nM for 48 hours. Following this period, cells were visually checked for adherence
and proper morphology before exchanging existing differentiation media to serum free
media for at least 24 hours prior to compound treatment.
Cranberry Extract (CE) was initially weighed and dissolved in PBS before being
diluted in cell culture medium at concentrations of 100 and 0.01 µg/mL. CE at these
concentrations were added to each respective set of wells for 1 hour before being
exposed to LPS at 1 µg/mL for 6 hours. Following LPS exposure, media was collected,
centrifuged and assayed for IL-6 and TNF-α using respective ELISA kits (Biolegend,
San Diego CA USA). We observed that LPS is able to stimulate the release of TNF-α
(1027 ± 27.4 pg/mL) and IL-6 (229.6 ± 12.69 pg/mL) into culture media whereas the
vehicle control did not produce significant levels (50.75 ± 0.05 pg/mL and 11.67 ± 0.18
pg/mL respectively). Resveratrol (RESV) was used at 20 µM and was found to decrease
concentrations of both TNF-α (944.8 ± 25.7 pg/mL) and IL-6 (44.3 ± 4.63 pg/mL). CE
at a concentrations of 0.01 µg/mL was the most effective at reducing the secretion of
TNF-α by 32% (694.7 ± 88.16 pg/mL) and at 0.1 µg/mL, IL-6 secretion was
significantly attenuated by approximately 72% (63.50 ± 3.5 pg/mL).
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Figure 16. Cranberry extract significantly attenuates the release of pro-inflammatory
TNF-α and IL-6 cytokines. Differentiated THP-1 Cells were pre-treated with vehicle
(DMSO), RESV (20 µM), or CE (100 to 0.01 µg/mL) for 1 hour before being exposed
to LPS (1 µg/mL) for 6 hours. Media was then collected and saved for cytokine analysis
with respective ELISAs. Data shown as mean ± SE. All comparisons made to LPS p <
0.05 * , p < 0.01 ** , p <0.001 ***, p<0.0001 ****.

To model the systemic exposure of dietary oligosaccharides from cranberry, THP1 monocytes, an immortalized human cell line was exploited for its ability to react to
various endogenous and exogenous stimuli. Moreover, these cells have been optimally
differentiated to macrophages effectively increasing their sensitivity to these stimuli.
Lipopolysaccharide is typically used to elicit an immune response by engaging TLR4
pathway further causing a release of pro-inflammatory/pro-oxidant signaling molecules.
Specifically, TNF-α and IL-6 are major drivers in this pathway and co-regulate each
other.
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The cytokines measured only represent a small portion of other possible signaling
molecules that interact with other monocytes, adipocytes and dendritic cells and other
surrounding tissues. More work is needed to construct a signaling network of cytokines
and chemokines. Gene expression data of these inflammation-based molecules has
already been explored by another group71 using a similar treatment methodology;
however, the composition of their extract is markedly different to this oligosaccharide
and terpenoid enriched fraction. Moreover, these macrophages respond to molecular
patterns from pathogen and damaged cells therefore, it is not unlikely that these
oligosaccharides may prevent the interaction of LPS or truly act upon a transcription
factor or protein target(s) within the cell. Further experiments are also warranted to
ascertain the extent of permeability and confirm which major constituents are
responsible for the possible anti-inflammatory effects of this cranberry extract.
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